Andrew Walczak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andrew Walczak has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Briony Hazelton
Perth Children's Hospital, Nedlands, WA, Australia; PathWest Laboratory Medicine, QEII, Nedlands, WA, Australia
1 shared publication Carmel Taylor
Forensic and Scientific Services Queensland Health Queensland Australia
1 shared publicationCarolien Giele
Communicable Disease Control Directorate, Department of Health Western Australia, Perth, WA, Australia
1 shared publication- David Anthony Foley
PathWest Laboratory Medicine Nedlands Western Australia Australia
1 shared publication David L. Mbbs Paterson
University of Queensland, UQ Centre for Clinical Research, Brisbane, Queensland, Australia
1 shared publicationDavid Reid
Adult Cystic Fibrosis Centre The Prince Charles Hospital Queensland Australia
1 shared publication
Latest Publications
- 3 November 2023
- Published by Sciencedomain International in Asian Journal of Research in Infectious Diseases
- Vol. 14 (4) , 152-164
Systematic Review of Carbapenem Resistant Gram-negative Infective Endocarditis, Treatment Options and Outcomes
Background: Gram negative infective endocarditis is rare and usually associated with intravenous drug use or significant healthcare exposure and prosthetic cardiac valves or devices. Carbapenem resistance is a growing concern worldwide with limited drug options for these infections especially serious high inoculum infections such as endocarditis. Methods: A systematic review examining treatment options and outcomes was conducted with identification of 12 cases in the literature. Results: Pseudomonas aeruginosa was the most common organism with left sided valvular involvement being most common. 18 different antibiotic regimens were used with surgery occurring in 5 cases (42%). In hospital mortality was 33% which increased at 6 months post episode. Increased age (p= 0.056) and CCI (p=0.006) appeared to be associated with death. Microbiological cure was more common in patients who received combination therapy with 2 active agents (75% successful) and combination therapy including an active beta-lactam agent (100% successful) but these did not meet statistical significance. Conclusions: Recommendations for management of this rare condition based on this systematic review and other available evidence are summarised in this review. Management should generally involve multidisciplinary teams, combination therapy with at least 2 active agents including a beta-lactam agent where possible with consideration of surgery in all cases. Evidence is however limited with need for ongoing publication of cases and further research to guide therapy in the future.
- 3 November 2023
- Published by Sciencedomain International in Asian Journal of Research in Infectious Diseases
- Vol. 14 (4) , 152-164
Systematic Review of Carbapenem Resistant Gram-negative Infective Endocarditis, Treatment Options and Outcomes
Background: Gram negative infective endocarditis is rare and usually associated with intravenous drug use or significant healthcare exposure and prosthetic cardiac valves or devices. Carbapenem resistance is a growing concern worldwide with limited drug options for these infections especially serious high inoculum infections such as endocarditis. Methods: A systematic review examining treatment options and outcomes was conducted with identification of 12 cases in the literature. Results: Pseudomonas aeruginosa was the most common organism with left sided valvular involvement being most common. 18 different antibiotic regimens were used with surgery occurring in 5 cases (42%). In hospital mortality was 33% which increased at 6 months post episode. Increased age (p= 0.056) and CCI (p=0.006) appeared to be associated with death. Microbiological cure was more common in patients who received combination therapy with 2 active agents (75% successful) and combination therapy including an active beta-lactam agent (100% successful) but these did not meet statistical significance. Conclusions: Recommendations for management of this rare condition based on this systematic review and other available evidence are summarised in this review. Management should generally involve multidisciplinary teams, combination therapy with at least 2 active agents including a beta-lactam agent where possible with consideration of surgery in all cases. Evidence is however limited with need for ongoing publication of cases and further research to guide therapy in the future.
- Open Access
- 31 March 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (13) , e32662
A contemporary case series of Pseudomonas aeruginosa infective endocarditis
Pseudomonas aeruginosa infective endocarditis (IE) is a rare disease associated with high mortality and complications. Here, we describe a contemporary set of patients aiming to improve the understanding of risk factors, clinical features, treatments, and outcomes. This retrospective case series reviewed cases from 3 tertiary metropolitan hospitals between January 1999 and January 2019. prespecified data were collected for each case, with a review of risk factors, valve involvement, acquisition, treatment, and complications. Fifteen patients were identified over a 20 years period. All patients presented with fever, 5/15 had preexisting prosthetic valve with valvular heart disease in 7/15 patients making it the most common risk factor. Intravenous drug use (IVDU) was the source in only 6/15 cases with healthcare associated infection and left-sided valvular involvement being more common than previous reports both occurring in 9/15 cases. Complications occurred in 11/15 patients with a 30 days mortality of 13%. Surgery was performed in 7/15 patients and 9/15 patients received antibiotic combination therapy. One year mortality was higher in those with increasing age, comorbidities, left-sided valve involvement, presence of predefined complications, and antibiotic monotherapy. Development of resistance occurred in 2 cases that received monotherapy. P aeruginosa IE remains a rare disease with high mortality and secondary complications.
- 31 March 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (13) , e32662
Open AccessA contemporary case series of Pseudomonas aeruginosa infective endocarditis
Pseudomonas aeruginosa infective endocarditis (IE) is a rare disease associated with high mortality and complications. Here, we describe a contemporary set of patients aiming to improve the understanding of risk factors, clinical features, treatments, and outcomes. This retrospective case series reviewed cases from 3 tertiary metropolitan hospitals between January 1999 and January 2019. prespecified data were collected for each case, with a review of risk factors, valve involvement, acquisition, treatment, and complications. Fifteen patients were identified over a 20 years period. All patients presented with fever, 5/15 had preexisting prosthetic valve with valvular heart disease in 7/15 patients making it the most common risk factor. Intravenous drug use (IVDU) was the source in only 6/15 cases with healthcare associated infection and left-sided valvular involvement being more common than previous reports both occurring in 9/15 cases. Complications occurred in 11/15 patients with a 30 days mortality of 13%. Surgery was performed in 7/15 patients and 9/15 patients received antibiotic combination therapy. One year mortality was higher in those with increasing age, comorbidities, left-sided valve involvement, presence of predefined complications, and antibiotic monotherapy. Development of resistance occurred in 2 cases that received monotherapy. P aeruginosa IE remains a rare disease with high mortality and secondary complications.
- 1 November 2020
- Published by Elsevier in Infection, Disease & Health
- Vol. 25 (4) , 239-241
COVID-19 in a complex obstetric patient with cystic fibrosis
- 1 November 2020
- Published by Elsevier in Infection, Disease & Health
- Vol. 25 (4) , 239-241
COVID-19 in a complex obstetric patient with cystic fibrosis